Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant V940 plus pembrolizumab versus placebo plus pembrolizumab in renal cell carcinoma
2023-505177-32-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial in renal cell carcinoma (RCC) comparing V940 plus pembrolizumab with Placebo plus pembrolizumab (2 arms). Primary endpoint: Disease-free survival. Planned start Jul 2024; status: authorised.
02
Drugs
intismeran autogenepembrolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2023-505177-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505177-32-00.